martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow?

View original at nasdaq.com
“Last year, Salesforce generated $14.4 billion of free cash flow, and it expects to grow that figure by 10% in fiscal 2027.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI fears over software disruption may be overblown, though confirmation will take years

    60% confidence

  • Salesforce will be able to harness AI to its advantage rather than be disrupted by it

    60% confidence

  • If signs emerge that Salesforce's platform will be one of the AI survivors or beneficiaries, it could be one of the best buys in the market

    60% confidence

  • Salesforce was not included in the 10 best stocks for investors to buy now

    60% confidence

  • If Salesforce's internal data and sales professionals can help customers use tokens more effectively in a proprietary way, that could be a recipe for generating value

    60% confidence

  • Salesforce expects to grow free cash flow by 10% in fiscal 2027

    60% confidence

  • It may take several quarterly earnings reports or updates to convince skeptics that the AI fears are overblown

    60% confidence

Data points we hold from this source

Salesforce · price to fcf9.5 ratio
Salesforce · net debt30 USD
Salesforce · shares outstanding810 millions
Salesforce · shares retired103 millions
Salesforce · share count reduction11.1 percent
Salesforce · shares outstanding923 millions
Salesforce · net debt5 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow? — Source | Via News | es.VIA.NEWS